A

Aytu BioPharma, Inc. (AYTU)

NCM – Real vaqt narxi. Valyuta: USD

2.30

-0.14 (-5.74%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

A

Aytu BioPharma, Inc. (AYTU)

NCM – Real vaqt narxi. Valyuta: USD

2.30

-0.14 (-5.74%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026

DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m.

04.02.2026

Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript

04.02.2026

Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates

Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.28 per share a year ago.

03.02.2026

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / February 3, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 second quarter.

02.02.2026

New Strong Sell Stocks for February 2nd

AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.

27.01.2026

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m.

21.01.2026

Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript

Videolar

No Data

There is no data to display

Press-relizlar

03.02.2026

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / February 3, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 second quarter.

20.01.2026

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided a summary of the Company's Investor Day, held today, Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City.

13.01.2026

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, at the Lytham Partners 2026 Investor Healthcare Summit. The webcast will take place at 5:00 p.m.

12.01.2026

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided additional details for its upcoming Investor Day, scheduled for Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City.

Search stocks

Aytu BioPharma, Inc. (AYTU)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Aytu BioPharma, Inc. (AYTU)

Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026

Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript

Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

New Strong Sell Stocks for February 2nd

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript

Videolar

No Data

Press-relizlar

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City